Kolexia
Menard Cedric Pharmacien
Menard Cedric
Pharmacien
Hôpital Pontchaillou
Rennes, France
70 Activités
74 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome B Lymphome folliculaire Complications postopératoires Protéinose alvéolaire pulmonaire Lymphome B diffus à grandes cellules Récidive tumorale locale Sclérodermie localisée Sclérodermie diffuse

Collaborateurs

Voir plus
Tarte Karin
Tarte Karin
Hôpital Pontchaillou, Rennes, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Houot Roch
Houot Roch
Hôpital Pontchaillou, Rennes, France
Cartron Guillaume
Cartron Guillaume
Hôpital Saint-Éloi, Montpellier, France

Industries

Voir plus
Edimark
2 collaboration(s)
Dernière en 2020
BMS
2 collaboration(s)
Dernière en 2023
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Nature medicine   31 octobre 2023
Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort.
Thorax   27 septembre 2023
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation: Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation
Essai Clinique (The Lymphoma Academic Research Organisation)   25 septembre 2023
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Nature medicine   14 septembre 2023
EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Regulatory B Cells Contribute to the Clinical Response After Bone Marrow-Derived Mesenchymal Stromal Cell Infusion in Patients With Systemic Sclerosis.
Stem cells translational medicine   19 avril 2023
Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma: A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   16 mars 2023
Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study
Annual Meeting Abstracts 2022   15 novembre 2022
Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study
Annual Meeting Abstracts 2022   15 novembre 2022